Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (261-270 of 868) with videos related to

Pageof 87
Sort By:
Leukemia & Lymphoma|May 20, 2009
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms MacroglobulinemiaJacob P Laubach, Constantine S Mitsiades, Aldo M Roccaro, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 15, 2010
Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myelomaSacha N Uljon, Paul G Richardson, Peter H Schur, et al.
Leukemia & Lymphoma|June 15, 2017
Overcoming multiple myeloma drug resistance in the era of cancer 'omics'Matthew Ho Zhi Guang, Amanda McCann, Giada Bianchi, et al.
Oncogene|September 19, 2003
Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cellsDharminder Chauhan, Guilan Li, Martin Sattler, et al.
Hematology. American Society of Hematology. Education Program|November 10, 2001
Multiple Myeloma: New Insights and Therapeutic ApproachesKenneth C. Anderson, Robert A. Kyle, William S. Dalton, et al.
Leukemia|April 15, 2024
Correction to: Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumorsJooeun Bae, Teru Hideshima, Yu-Tzu Tai, et al.
Haematologica|May 12, 2018
Meaningful changes in end-of-life care among patients with myelomaOreofe O Odejide, Ling Li, Angel M Cronin, et al.
The Journal of Biological Chemistry|April 1, 2003
JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cellsDharminder Chauhan, Guilan Li, Teru Hideshima, et al.
Molecular Cancer Therapeutics|December 14, 2002
The biological sequelae of stromal cell-derived factor-1alpha in multiple myelomaTeru Hideshima, Dharminder Chauhan, Toshiaki Hayashi, et al.
Leukemia|March 1, 2018
Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumorsJooeun Bae, Teru Hideshima, Yu-Tzu Tai, et al.
Pageof 87

Showing results (261-270 of 868) with videos related to

Sort By:
Pageof 87
Leukemia & Lymphoma|May 20, 2009
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms MacroglobulinemiaJacob P Laubach, Constantine S Mitsiades, Aldo M Roccaro, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 15, 2010
Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myelomaSacha N Uljon, Paul G Richardson, Peter H Schur, et al.
Leukemia & Lymphoma|June 15, 2017
Overcoming multiple myeloma drug resistance in the era of cancer 'omics'Matthew Ho Zhi Guang, Amanda McCann, Giada Bianchi, et al.
Oncogene|September 19, 2003
Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cellsDharminder Chauhan, Guilan Li, Martin Sattler, et al.
Hematology. American Society of Hematology. Education Program|November 10, 2001
Multiple Myeloma: New Insights and Therapeutic ApproachesKenneth C. Anderson, Robert A. Kyle, William S. Dalton, et al.
Leukemia|April 15, 2024
Correction to: Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumorsJooeun Bae, Teru Hideshima, Yu-Tzu Tai, et al.
Haematologica|May 12, 2018
Meaningful changes in end-of-life care among patients with myelomaOreofe O Odejide, Ling Li, Angel M Cronin, et al.
The Journal of Biological Chemistry|April 1, 2003
JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cellsDharminder Chauhan, Guilan Li, Teru Hideshima, et al.
Molecular Cancer Therapeutics|December 14, 2002
The biological sequelae of stromal cell-derived factor-1alpha in multiple myelomaTeru Hideshima, Dharminder Chauhan, Toshiaki Hayashi, et al.
Leukemia|March 1, 2018
Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumorsJooeun Bae, Teru Hideshima, Yu-Tzu Tai, et al.
Pageof 87